CNBC July 7, 2023
Key Points
– Sales of the Alzheimer’s drug Leqembi may be slow initially due to logistical requirements but could pick up in 2024, analysts said.
– Wall Street is chewing over the Food and Drug Administration’s Thursday approval of Biogen and Eisai’s Leqembi.
– It’s the first medicine proven to slow the progression of Alzheimer’s in people at the early stages of the memory-robbing disease.
Sales of the Alzheimer’s drug Leqembi may be slow initially due to logistical requirements but could pick up in 2024, analysts said after the groundbreaking treatment won approval in the U.S.
Wall Street is chewing over the Food and Drug Administration‘s Thursday approval of Leqembi – a milestone in the treatment of the...
Today's Sponsors
Today's Sponsor